Agreements reached under this partnership
Business alliance- 1
The Company has granted Hisamitsu Pharmaceutical Co., Inc. exclusive worldwide rights to develop, manufacture and market the compound.
- 2
The Company retains the right to receive development-stage milestones, as well as sales royalties based on product sales and sales milestones after the product is launched.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The ¥200 million upfront payment will be recognized as business revenue in the fourth quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the year announced on 13 February 2026, and there will be no change to the earnings forecast as a result of this matter.
| Item | Details |
|---|---|
| Name of alliance partner | Hisamitsu Pharmaceutical Co., Inc. |
| Type of alliance | Business alliance |
| Details of the alliance | The Company has granted Hisamitsu Pharmaceutical Co., Inc. exclusive worldwide rights to develop, manufacture and market the compound., The Company retains the right to receive development-stage milestones, as well as sales royalties based on product sales and sales milestones after the product is launched. |
| Contract Date | December 2021 |
| Impact on Business Performance | The ¥200 million upfront payment will be recognized as business revenue in the fourth quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the year announced on 13 February 2026, and there will be no change to the earnings forecast as a result of this matter. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company received notification from Hisamitsu Pharmaceutical Co., Inc. that the Phase II clinical trials had begun. Under the agreement, the Company will receive upfront payments based on the stage of development.